MAS CELL PRODUCT MANUFACTURER REGISTRATION DUE BY LATE NOVEMBER, IND/BLA IN 18 MONTHS, FDA SAYS; SHORT-TERM DATA GENERALLY ACCEPTABLE TO SHOW EFFICACY
This article was originally published in The Gray Sheet
Manufacturers of autologous cell products for structural repair must register as drug manufacturers with FDA by the end of November, according to the agency's plan for regulating the products. The policy covers products comprised of living autologous cells manipulated ex vivo and intended for structural repair or reconstruction (MAS cells).
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.